The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “March 2017” and All Insider Sales to “$5,000,000+.”
According to the above filters, the following are trades from company insiders this week.
National General Holdings Corp. (NGHC) CEO and President Karfunkel Barry bought 31,600 shares for $22.93 per share on March 30. Since then, the stock price has risen to $23.59.
It is a specialty personal lines insurance holding company. Through its subsidiaries it provides insurance products including personal and commercial automobile, supplemental health, homeowners and umbrella.
The company has an institutional ownership of 39.57% and insider ownership of 11.88%.
Over the last 12 months, the stock price has risen by 9% and is now trading with a price-book (P/B) ratio of 1.72. The price is 12.60% below its 52-week high and 30.76% above its 52-week low.
Vital Therapies Inc. (VTL) 10% owner and Director Muneer A. Satler bought 3.75 million shares for $4.00 per share on March 27. The stock price has risen to $4.10 since.
It is a biotherapeutic company. The company is engaged in developing a cell-based therapy targeting treatment of all forms of acute liver failure. Its products include the ELAD System, an extracorporeal bioartificial liver support system.
The company has an institutional ownership of 40.36% and insider ownership of 1.55%.
Over the last 12 months, the stock price has dropped by 56% and is now trading with a P/B ratio of 2.29. The price is 58.29% below its 52-week high and 9.46% above its 52-week low.
Fifth Street Finance Corp. (FSC) 10% owner Leonardo M. Tannenbaum bought 10,023,923 shares for $4.70 per share on March 27 and 29. Since then, the stock price has dropped to $4.56.
It is a speciality finance company. It invests in small and midsized companies in connection with investments by private equity sponsors.
The company has an institutional ownership of 34.66% and insider ownership of 10.13%.
Over the last 12 months, the stock price has dropped by 5% and is now trading with a P/B ratio of 0.62. The price is 25.63% below its 52-week high and 9.05% above its 52-week low.
Sears Holdings Corp. (SHLD) Director and 10% owner Fairholme Capital Management LLC bought 286,600 shares for $8.13 per share on March 27. The stock price has climbed to $11.75 since.
Along with its subsidiaries it is an integrated retailer with full-line and specialty retail stores in the U.S., operating through Kmart and Sears.
The company has an institutional ownership of 66.06% and insider ownership of 1.63%.
Over the last 12 months, the stock price has dropped by 24%; the price is 39.85% below its 52-week high and 109.09% above its 52-week low.
Most important sales of the week
Eagle Pharmaceuticals Inc. (EGRX) 10% owner ProQuest Investments IV LP sold 106,468 shares for $83.01 per share on March 29. Since then, the stock price decreased to $82.87.
It is a specialty pharmaceutical company. It develops and commercializes injectable products primarily in the critical care and oncology areas.
The company has an institutional ownership of 96.74% and insider ownership of 9.02%.
Over the last 12 months, the stock price has risen by 105% and is now trading with a P/B ratio of 8.38. The price is 5.59% below its 52-week high and 150.97% above its 52-week low.
McKesson Corp. (MCK) Chairman, President and CEO John H. Hammergren sold 100,500 shares for $150.44 per share on March 29. Since then, the stock price has declined to $149.48.
It distributes pharmaceuticals, medical supplies and health care information technology that make health care safer while reducing costs.
The company has an institutional ownership of 82.94% and insider ownership of 0.10%.
Over the last 12 months, the stock price has dropped by 5% and is now trading with a P/B ratio of 4.39 .The price is 25.05% below its 52-week high and 30.52% above its 52-week low.
Fidelity National Information Services Inc. (FIS) Director Frank R. Martire sold 219,017 shares for $80.02 per share on March 27. The stock price has not changed.
It provides banking and payments technologies solutions. Its segments includes Financial Solutions Group, Payment Solutions Group, International Solutions Group, Corporate and Other.
The company has an institutional ownership of 99.57% and insider ownership of 1.04%.
Over the last 12 months, the stock price has risen by 27% and is now trading with a P/B ratio of 2.70. The price is 4.57% below its 52-week high and 28.98% above its 52-week low.
CytomX Therapeutics Inc. (CTMX) 10% owner Third Rock Ventures LP sold 1.65 million shares for $17.39 per share on March 27. Since then, the stock price has declined to $17.26.
It is an oncology-focused biopharmaceutical company and is engaged in developing Probody therapeutics that address clinically validated cancer targets in immuno-oncology, such as PD-L1, as well as targets such as CD-166.
The company has an institutional ownership of 73.54% and insider ownership of 0.78%.
Over the last 12 months, the stock price has risen by 34% and is now trading with a P/B ratio of 7.90. The price is 15.08% below its 52-week high and 63.46% above its 52-week low.
Disclosure: I do not own any shares of any stocks mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
